MX2020005561A - Proteinas modificadas de union a adn. - Google Patents

Proteinas modificadas de union a adn.

Info

Publication number
MX2020005561A
MX2020005561A MX2020005561A MX2020005561A MX2020005561A MX 2020005561 A MX2020005561 A MX 2020005561A MX 2020005561 A MX2020005561 A MX 2020005561A MX 2020005561 A MX2020005561 A MX 2020005561A MX 2020005561 A MX2020005561 A MX 2020005561A
Authority
MX
Mexico
Prior art keywords
dna
modified proteins
binding modified
binding
modulates
Prior art date
Application number
MX2020005561A
Other languages
English (en)
Spanish (es)
Inventor
Kartik Ramamoorthi
Andrew Young
Stephanie Tagliatela
David Oberkofler
Anne Tanenhaus
Original Assignee
Encoded Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Encoded Therapeutics Inc filed Critical Encoded Therapeutics Inc
Publication of MX2020005561A publication Critical patent/MX2020005561A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/30—Vector systems having a special element relevant for transcription being an enhancer not forming part of the promoter region

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2020005561A 2017-12-01 2018-11-30 Proteinas modificadas de union a adn. MX2020005561A (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201762593824P 2017-12-01 2017-12-01
US201762610014P 2017-12-22 2017-12-22
US201862618966P 2018-01-18 2018-01-18
US201862641806P 2018-03-12 2018-03-12
US201862646198P 2018-03-21 2018-03-21
US201862664814P 2018-04-30 2018-04-30
US201862664817P 2018-04-30 2018-04-30
PCT/US2018/063498 WO2019109051A1 (en) 2017-12-01 2018-11-30 Engineered dna binding proteins

Publications (1)

Publication Number Publication Date
MX2020005561A true MX2020005561A (es) 2020-10-12

Family

ID=66664596

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005561A MX2020005561A (es) 2017-12-01 2018-11-30 Proteinas modificadas de union a adn.

Country Status (15)

Country Link
US (2) US12083188B2 (enExample)
EP (1) EP3717505A4 (enExample)
JP (3) JP7401432B2 (enExample)
KR (1) KR20200107949A (enExample)
CN (2) CN118345115A (enExample)
AU (2) AU2018375192B2 (enExample)
BR (1) BR112020010883A2 (enExample)
CA (1) CA3083765A1 (enExample)
CL (1) CL2020001451A1 (enExample)
IL (2) IL274926B1 (enExample)
MA (1) MA50942A (enExample)
MX (1) MX2020005561A (enExample)
SG (1) SG11202004926WA (enExample)
TW (3) TWI835761B (enExample)
WO (1) WO2019109051A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3359685A1 (en) 2015-10-09 2018-08-15 University Of Southampton Modulation of gene expression and screening for deregulated protein expression
US11083745B2 (en) 2015-12-14 2021-08-10 Cold Spring Harbor Laboratory Antisense oligomers for treatment of autosomal dominant mental retardation-5 and Dravet Syndrome
EP3624858A4 (en) * 2017-05-19 2021-06-23 Encoded Therapeutics, Inc. HIGHLY ACTIVE REGULATORY ELEMENTS
SMT202400071T1 (it) 2017-08-25 2024-03-13 Stoke Therapeutics Inc Oligomeri antisenso per il trattamento di condizioni e malattie
AU2018375192B2 (en) 2017-12-01 2023-11-09 Encoded Therapeutics, Inc. Engineered DNA binding proteins
CN117534769A (zh) 2018-04-19 2024-02-09 加利福尼亚大学董事会 用于基因编辑的组合物和方法
JP2021523227A (ja) 2018-05-04 2021-09-02 ストーク セラピューティクス，インク． コレステリルエステル蓄積症の処置のための方法及び組成物
TWI872078B (zh) 2019-05-29 2025-02-11 美商編碼製藥公司 用於選擇性基因調節的組合物和方法
JP2022548399A (ja) * 2019-09-23 2022-11-18 オメガ セラピューティクス， インコーポレイテッド 肝細胞核因子４－アルファ（ＨＮＦ４α）遺伝子発現をモジュレートするための組成物および方法
GB201913974D0 (en) * 2019-09-27 2019-11-13 King S College London Vector
CA3166986A1 (en) * 2020-01-07 2021-07-15 Sumitomo Pharma Co., Ltd. Therapeutic agent for tauopathies
CA3173647A1 (en) 2020-05-11 2021-11-18 Isabel AZNAREZ Opa1 antisense oligomers for treatment of conditions and diseases
JP2023526267A (ja) 2020-05-13 2023-06-21 エフ． ホフマン－ラ ロシュ アーゲー プログラニュリン標的オリゴヌクレオチドアゴニスト
US20230279405A1 (en) * 2020-07-24 2023-09-07 University Of Massachusetts Dna-binding domain transactivators and uses thereof
WO2022125420A1 (en) * 2020-12-09 2022-06-16 City Of Hope Compounds and methods to treat cystic fibrosis
CN115074389A (zh) * 2022-06-13 2022-09-20 华南农业大学 稳定表达鸭坦布苏病毒ns1蛋白的细胞系的构建方法及其应用
WO2024145499A2 (en) * 2022-12-29 2024-07-04 Encoded Therapeutics, Inc. Materials and methods for characterizing potency

Family Cites Families (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140466A (en) 1994-01-18 2000-10-31 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
CA2681922C (en) 1994-01-18 2012-05-15 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
EP0755454B1 (en) 1994-04-13 2008-02-13 The Rockefeller University Aav-mediated delivery of dna to cells of the nervous system
GB9824544D0 (en) 1998-11-09 1999-01-06 Medical Res Council Screening system
JP4118327B2 (ja) 1994-08-20 2008-07-16 ゲンダック・リミテッド Ｄｎａ認識のための結合タンパク質におけるまたはそれに関連する改良
US5789538A (en) 1995-02-03 1998-08-04 Massachusetts Institute Of Technology Zinc finger proteins with high affinity new DNA binding specificities
US5925523A (en) 1996-08-23 1999-07-20 President & Fellows Of Harvard College Intraction trap assay, reagents and uses thereof
NZ333334A (en) 1997-04-17 2001-06-29 Frank L Sorgi Delivery system for gene therapy to the brain
CA2205076A1 (en) 1997-05-14 1998-11-14 Jim Hu Episomal expression cassettes for gene therapy
GB9710807D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
US6995006B2 (en) 1997-09-05 2006-02-07 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
ATE466952T1 (de) 1998-03-02 2010-05-15 Massachusetts Inst Technology Poly-zinkfinger-proteine mit verbesserten linkern
US6303370B1 (en) 1998-03-24 2001-10-16 Mayo Foundation For Medical Education And Research Tissue-specific regulatory elements
CA2246005A1 (en) 1998-10-01 2000-04-01 Hsc Research And Development Limited Partnership Hybrid genes for gene therapy in erythroid cells
US6140081A (en) 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
US7070934B2 (en) 1999-01-12 2006-07-04 Sangamo Biosciences, Inc. Ligand-controlled regulation of endogenous gene expression
US6599692B1 (en) 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US7030215B2 (en) 1999-03-24 2006-04-18 Sangamo Biosciences, Inc. Position dependent recognition of GNN nucleotide triplets by zinc fingers
US6794136B1 (en) 2000-11-20 2004-09-21 Sangamo Biosciences, Inc. Iterative optimization in the design of binding proteins
US20030104526A1 (en) * 1999-03-24 2003-06-05 Qiang Liu Position dependent recognition of GNN nucleotide triplets by zinc fingers
US6649371B1 (en) 1999-06-11 2003-11-18 Neurosearch A/S Potassium channel KCNQ5 and sequences encoding the same
US7329728B1 (en) * 1999-10-25 2008-02-12 The Scripps Research Institute Ligand activated transcriptional regulator proteins
WO2001036620A2 (en) 1999-11-16 2001-05-25 Genzyme Corporation Vectors and transgenies with regulatory elements for gene delivery to the liver
EP1103610A1 (en) 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
AU1846501A (en) 1999-11-26 2001-06-04 Bionomics Limited Loci for idiopathic generalized epilepsy, mutations thereof and method using same to assess, diagnose, prognose or treat epilepsy
DE60023936T2 (de) 1999-12-06 2006-05-24 Sangamo Biosciences Inc., Richmond Methoden zur verwendung von randomisierten zinkfingerprotein-bibliotheken zur identifizierung von genfunktionen
US6689558B2 (en) 2000-02-08 2004-02-10 Sangamo Biosciences, Inc. Cells for drug discovery
US20020061512A1 (en) 2000-02-18 2002-05-23 Kim Jin-Soo Zinc finger domains and methods of identifying same
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
ATE353361T1 (de) 2000-04-28 2007-02-15 Sangamo Biosciences Inc Gezielten modifikation der chromatinstruktur
FR2808803B1 (fr) 2000-05-11 2004-12-10 Agronomique Inst Nat Rech Cellules es modifiees et gene specifique de cellules es
US20030044787A1 (en) 2000-05-16 2003-03-06 Joung J. Keith Methods and compositions for interaction trap assays
JP2004514413A (ja) 2000-06-07 2004-05-20 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド ヒトの電位依存性ナトリウムチャンネルβ−１Ａサブユニットおよび使用法
JP2002060786A (ja) 2000-08-23 2002-02-26 Kao Corp 硬質表面用殺菌防汚剤
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US6919204B2 (en) 2000-09-29 2005-07-19 Sangamo Biosciences, Inc. Modulation of gene expression using localization domains
USH2191H1 (en) 2000-10-24 2007-06-05 Snp Consortium Identification and mapping of single nucleotide polymorphisms in the human genome
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
CA2435394C (en) * 2001-01-22 2018-01-09 Sangamo Biosciences, Inc. Modified zinc finger binding proteins
US20030051266A1 (en) 2001-02-14 2003-03-13 Serafini Tito Andrew Collections of transgenic animal lines (living library)
US7067617B2 (en) 2001-02-21 2006-06-27 The Scripps Research Institute Zinc finger binding domains for nucleotide sequence ANN
DE60233555D1 (de) * 2001-02-21 2009-10-15 Novartis Ag Die nukleotidsequenz ann bindende zink-finger domänen
GB0108491D0 (en) 2001-04-04 2001-05-23 Gendaq Ltd Engineering zinc fingers
AUPR492201A0 (en) 2001-05-10 2001-06-07 Bionomics Limited Novel mutation
WO2003004660A1 (en) 2001-07-03 2003-01-16 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods of administering vectors to synaptically connected neurons
US20040224385A1 (en) 2001-08-20 2004-11-11 Barbas Carlos F Zinc finger binding domains for cnn
US6998118B2 (en) 2001-12-21 2006-02-14 The Salk Institute For Biological Studies Targeted retrograde gene delivery for neuronal protection
US7262054B2 (en) 2002-01-22 2007-08-28 Sangamo Biosciences, Inc. Zinc finger proteins for DNA binding and gene regulation in plants
WO2003066828A2 (en) * 2002-02-07 2003-08-14 The Scripps Research Institute Zinc finger libraries
CA2474751A1 (en) 2002-02-25 2003-09-04 Vanderbilt University Expression system for human brain-specific voltage-gated sodium channel, type 1
FR2836924B1 (fr) 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
US7361635B2 (en) 2002-08-29 2008-04-22 Sangamo Biosciences, Inc. Simultaneous modulation of multiple genes
US7482117B2 (en) 2002-12-20 2009-01-27 Celera Corporation Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof
DK1590467T3 (da) 2003-01-28 2010-01-18 Hoffmann La Roche Anvendelse af regulatoriske sekvenser til specifik, transient ekspression i neuronalt bestemte celler
US20040258666A1 (en) 2003-05-01 2004-12-23 Passini Marco A. Gene therapy for neurometabolic disorders
JP4559429B2 (ja) 2003-05-21 2010-10-06 ジェンザイム・コーポレーション 空キャプシドを実質的に含まない組換えａａｖビリオン調製物を生成するための方法
US7094600B2 (en) 2003-06-26 2006-08-22 The Research Foundation Of State University Of New York Screen for sodium channel modulators
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
WO2005068664A2 (en) 2004-01-09 2005-07-28 The Regents Of The University Of California Cell-type-specific patterns of gene expression
US7972854B2 (en) 2004-02-05 2011-07-05 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
ES2527528T3 (es) 2004-04-08 2015-01-26 Sangamo Biosciences, Inc. Métodos y composiciones para modular la contractilidad cardiaca
AU2005233550B2 (en) 2004-04-08 2010-11-18 Sangamo Therapeutics, Inc. Treatment of neuropathic pain with zinc finger proteins
DE602005011943D1 (de) 2004-04-08 2009-02-05 Sangamo Biosciences Inc Zusammensetzungen zur behandlung von neuropathischen und neurodegenerativen erkrankungen
CN101137755A (zh) 2004-04-14 2008-03-05 新加坡科技研究局 用于向神经元细胞基因送递的方法
TWI293307B (en) 2004-09-30 2008-02-11 Ind Tech Res Inst A liver-specific chimeric regulatory sequence and use thereof
ATE553122T1 (de) 2005-02-28 2012-04-15 Sangamo Biosciences Inc Antiangiogene methoden und zusammensetzungen
FR2884255B1 (fr) 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
SI2002003T1 (sl) 2005-05-27 2016-05-31 Ospedale San Raffaele S.R.L. Genski vektor, ki vsebuje mi-RNA
WO2007019062A2 (en) 2005-08-11 2007-02-15 The Scripps Research Institute Zinc finger binding domains for cnn
EP1783645A1 (en) 2005-11-08 2007-05-09 Actigenics Methods for the identification of microRNA and their applications in research and human health
US8048999B2 (en) 2005-12-13 2011-11-01 Kyoto University Nuclear reprogramming factor
EP2021499A4 (en) 2005-12-16 2010-02-17 Univ Leland Stanford Junior FUNCTIONAL ARRAYS FOR THE IDENTIFICATION OF ELEMENTS FOR GENE PRESSION REGULATION WITH HIGH THROUGHPUT
US20070161031A1 (en) 2005-12-16 2007-07-12 The Board Of Trustees Of The Leland Stanford Junior University Functional arrays for high throughput characterization of gene expression regulatory elements
JP4144637B2 (ja) 2005-12-26 2008-09-03 セイコーエプソン株式会社 印刷材収容体、基板、印刷装置および印刷材収容体を準備する方法
CA2645186A1 (en) 2006-01-20 2007-07-26 The Regents Of The University Of California Transplantation of neural cells
KR20090031938A (ko) 2006-07-05 2009-03-30 더 스크립스 리서치 인스티튜트 방향성 진화로 촉매 작용을 최적화시킨 키메라 징크 핑거 리컴비나제
EP2089398A2 (en) 2006-10-25 2009-08-19 Polyera Corporation Organic semiconductor materials and methods of preparing and use thereof
EP2097538A4 (en) 2006-12-07 2011-11-30 Switchgear Genomics TRANSCRIPTION REAGULATION ELEMENTS OF BIOLOGICAL PATHS, TOOLS AND METHODS
EP2137296A2 (en) 2007-03-23 2009-12-30 Wisconsin Alumni Research Foundation Somatic cell reprogramming
EP1985305A1 (en) 2007-04-24 2008-10-29 Vivalis Duck embryonic derived stem cell lines for the production of viral vaccines
EP1995309A1 (en) 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
EP2019143A1 (en) 2007-07-23 2009-01-28 Genethon CNS gene delivery using peripheral administration of AAV vectors
WO2009060316A2 (en) * 2007-09-14 2009-05-14 The Governors Of The University Of Alberta Hepatitis b virus-binding polypeptides and methods of use thereof
ITRM20070523A1 (it) 2007-10-05 2009-04-06 Consiglio Nazionale Ricerche Acido nucleico codificante per una proteina regolatrice specifica della trascrizione dell'utrofina proteina da esso codificata e sue applicazioni
US20100297674A1 (en) 2008-01-22 2010-11-25 Chromocell Corporation NOVEL CELL LINES EXPRESSING NaV AND METHODS USING THEM
US20110165129A1 (en) 2008-05-06 2011-07-07 Arnold Kriegstein Ameliorating Nervous Systems Disorders
US9267151B2 (en) 2008-08-20 2016-02-23 Brainco Biopharma, S.L. STXBP1 overexpressing mouse and its uses in screening of treatments for neuropsychiatric illness
WO2010037143A1 (en) 2008-09-29 2010-04-01 The University Of Montana Vectors and methods of treating brain seizures
SMT201800554T1 (it) 2009-06-16 2018-11-09 Genzyme Corp Metodi migliorati per la purificazione di vettori di aav ricombinanti
GB0911870D0 (en) 2009-07-08 2009-08-19 Ucl Business Plc Optimised coding sequence and promoter
US8815779B2 (en) 2009-09-16 2014-08-26 SwitchGear Genomics, Inc. Transcription biomarkers of biological responses and methods
US20110135611A1 (en) 2009-12-03 2011-06-09 The J. David Gladstone Institutes Methods for treating apolipoprotein e4-associated disorders
US20110203007A1 (en) 2010-02-16 2011-08-18 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Assays of neurodegenerative disorders, including frontotemporal dementia and amyotrophic lateral sclerosis
US9315825B2 (en) 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
EP3540055A1 (en) 2010-04-23 2019-09-18 University of Massachusetts Cns targeting aav vectors and methods of use thereof
US8927514B2 (en) 2010-04-30 2015-01-06 City Of Hope Recombinant adeno-associated vectors for targeted treatment
CN102959087B (zh) 2010-05-03 2015-04-29 桑格摩生物科学股份有限公司 用于连接锌指模块的组合物
CN103025344B (zh) 2010-05-17 2016-06-29 桑格摩生物科学股份有限公司 新型dna-结合蛋白及其用途
KR101914309B1 (ko) 2010-06-23 2018-11-02 큐알엔에이, 인크. 전압 작동 나트륨 통로, 알파 소단위(scna)에 대한 자연 안티센스 전사체의 저해에 의한 전압 작동 나트륨 통로, 알파 소단위(scna) 관련된 질환의 치료
EP2634253B1 (en) 2010-10-27 2016-05-11 Jichi Medical University Adeno-associated virus virions for transferring genes into neural cells
EP2635686B1 (en) 2010-11-05 2018-03-28 The Regents of The University of California Neuronal specific targeting of caveolin expression to restore synaptic signaling and improve cognitive function in the neurodegenerative brain and motor function in spinal cord
WO2012087983A1 (en) 2010-12-20 2012-06-28 The General Hospital Corporation Polycomb-associated non-coding rnas
EP2638163B1 (en) 2010-11-12 2017-05-17 The General Hospital Corporation Polycomb-associated non-coding rnas
US10392632B2 (en) 2011-02-14 2019-08-27 The Children's Hospital Of Philadelphia AAV8 vector with enhanced functional activity and methods of use thereof
US20130129668A1 (en) 2011-09-01 2013-05-23 The Regents Of The University Of California Diagnosis and treatment of arthritis using epigenetics
CN103874486A (zh) 2011-09-06 2014-06-18 库尔纳公司 用小分子治疗与电压门控钠通道的α亚基(SCNxA)相关的疾病
KR20120087860A (ko) 2012-02-03 2012-08-07 주식회사 툴젠 신규한 징크 핑거 뉴클레아제 및 이의 용도
CN104520428B (zh) 2012-02-17 2018-09-21 费城儿童医院 将基因转移到细胞、器官和组织的aav载体组合物和方法
AU2013201287B2 (en) 2012-03-06 2015-05-14 Duke University Synthetic regulation of gene expression
WO2013155222A2 (en) 2012-04-10 2013-10-17 The Regents Of The University Of California Brain-specific enhancers for cell-based therapy
CN105188767A (zh) * 2012-07-25 2015-12-23 布罗德研究所有限公司 可诱导的dna结合蛋白和基因组干扰工具及其应用
WO2014052855A1 (en) 2012-09-27 2014-04-03 Population Diagnostics, Inc. Methods and compositions for screening and treating developmental disorders
WO2014066700A1 (en) 2012-10-25 2014-05-01 Tocagen Inc. Retroviral vector with mini-promoter cassette
HK1220488A1 (zh) 2013-03-15 2017-05-05 The Children's Hospital Of Philadelphia 含有填充者/填充物多核苷酸序列的载体及其使用方法
AR095982A1 (es) * 2013-04-03 2015-11-25 Aliophtha Ag Factores de transcripción artificiales modificados genéticamente para superar el atrapamiento endosómico
AR095984A1 (es) * 2013-04-03 2015-11-25 Aliophtha Ag Factores artificiales de transcripción que regulan receptores nucleares y su uso terapéutico
CA2912678C (en) 2013-05-15 2023-10-10 Regents Of The University Of Minnesota Adeno-associated virus mediated gene transfer to the central nervous system
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
PT3060237T (pt) * 2013-10-25 2021-11-09 Univ Wayne State Proteína de reprogramação modificada para utilização no tratamento de um cancro
EP3119878B1 (en) 2014-03-18 2021-05-26 Sangamo Therapeutics, Inc. Methods and compositions for regulation of zinc finger protein expression
WO2015153760A2 (en) * 2014-04-01 2015-10-08 Sangamo Biosciences, Inc. Methods and compositions for prevention or treatment of a nervous system disorder
EP3152319A4 (en) 2014-06-05 2017-12-27 Sangamo BioSciences, Inc. Methods and compositions for nuclease design
US10301367B2 (en) 2014-07-26 2019-05-28 Consiglio Nazionale Delle Ricerche Compositions and methods for treatment of muscular dystrophy
JP6865167B2 (ja) 2014-12-17 2021-04-28 フンダシオン パラ ラ インベスティガシオン メディカ アプリカダ ウィルソン病の処置に使用するための核酸構築物及び遺伝子治療ベクター
TWI707951B (zh) 2015-04-08 2020-10-21 美商健臻公司 過大腺相關載體之製造
US11020443B2 (en) 2015-04-23 2021-06-01 University Of Massachusetts Modulation of AAV vector transgene expression
CN104846015B (zh) 2015-05-27 2018-03-27 深圳先进技术研究院 特异性兴奋伏隔核中的gaba能神经元的组合物及其在改善精神分裂症异样行为中的应用
WO2017048466A1 (en) * 2015-09-15 2017-03-23 The Regents Of The University Of California Compositions and methods for delivering biotherapeutics
EP3368054A4 (en) 2015-10-28 2019-07-03 Voyager Therapeutics, Inc. REGULATORY EXPRESSION USING THE ADENO-ASSOCIATED VIRUS (AAV)
HK1258413A1 (zh) 2015-10-29 2019-11-08 Voyager Therapeutics, Inc. 遞送中樞神經系統(cns)靶向多核苷酸
US11083745B2 (en) * 2015-12-14 2021-08-10 Cold Spring Harbor Laboratory Antisense oligomers for treatment of autosomal dominant mental retardation-5 and Dravet Syndrome
JP7436089B2 (ja) 2016-03-02 2024-02-21 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア 前頭側頭型認知症の治療
US20190127713A1 (en) * 2016-04-13 2019-05-02 Duke University Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
CA3035910A1 (en) 2016-09-07 2018-03-15 Flagship Pioneering, Inc. Methods and compositions for modulating gene expression
JP2018088888A (ja) 2016-12-06 2018-06-14 国立研究開発法人理化学研究所 Ｓｃｎ１ａ遺伝子の発現増強法
MX2019007873A (es) 2016-12-30 2019-11-18 Univ Pennsylvania Terapia génica para tratar la enfermedad de wilson.
EP3579858A4 (en) 2017-02-07 2020-12-23 The Regents of The University of California GENE THERAPY AGAINST HAPLOINSUFFICIENCY
CN117821509A (zh) 2017-04-03 2024-04-05 编码治疗公司 组织选择性转基因表达
EP3624858A4 (en) 2017-05-19 2021-06-23 Encoded Therapeutics, Inc. HIGHLY ACTIVE REGULATORY ELEMENTS
AU2018375192B2 (en) 2017-12-01 2023-11-09 Encoded Therapeutics, Inc. Engineered DNA binding proteins
WO2019224864A1 (ja) 2018-05-21 2019-11-28 国立研究開発法人理化学研究所 Ｓｃｎ１ａ遺伝子の発現増強法とそれによるドラベ症候群の治療法
BR112021016783A2 (pt) 2019-02-28 2021-11-09 Encoded Therapeutics Inc Composições e métodos para tratar laminopatias
TWI872078B (zh) 2019-05-29 2025-02-11 美商編碼製藥公司 用於選擇性基因調節的組合物和方法

Also Published As

Publication number Publication date
CN111727259A (zh) 2020-09-29
AU2018375192A1 (en) 2020-07-02
TW202421790A (zh) 2024-06-01
KR20200107949A (ko) 2020-09-16
CL2020001451A1 (es) 2020-11-06
US12083188B2 (en) 2024-09-10
JP7401432B2 (ja) 2023-12-19
JP2022171792A (ja) 2022-11-11
TW201925474A (zh) 2019-07-01
CN111727259B (zh) 2024-04-19
IL323220A (en) 2025-11-01
AU2023285810A1 (en) 2024-01-18
BR112020010883A2 (pt) 2020-11-10
IL274926B1 (en) 2025-12-01
JP7634507B2 (ja) 2025-02-21
CN118345115A (zh) 2024-07-16
CA3083765A1 (en) 2019-06-06
WO2019109051A1 (en) 2019-06-06
SG11202004926WA (en) 2020-06-29
MA50942A (fr) 2020-10-07
AU2018375192B2 (en) 2023-11-09
US20240408242A1 (en) 2024-12-12
EP3717505A1 (en) 2020-10-07
US20200397917A1 (en) 2020-12-24
JP2024069591A (ja) 2024-05-21
TW202319538A (zh) 2023-05-16
TWI835761B (zh) 2024-03-21
JP2021505133A (ja) 2021-02-18
IL274926A (en) 2020-07-30
EP3717505A4 (en) 2021-12-01

Similar Documents

Publication Publication Date Title
CL2020001451A1 (es) Proteínas modificadas de unión a adn.
AR122050A2 (es) Proteínas de fusión, bacterias recombinantes y métodos de uso de las bacterias recombinantes
PH12020551716A1 (en) Anti-ror antibody constructs
CL2019002605A1 (es) Formulaciones que contienen proteínas de unión pd-1 y métodos de fabricación de las mismas.
CO2020005981A2 (es) Anticuerpos anti-tau y uso de los mismos
BR112019012342A2 (pt) anticorpos il-11
EA202090090A1 (ru) Включение неприродных нуклеотидов и способы с ними
WO2018075692A3 (en) Antibody constructs
EP3459597A4 (en) SINGLE DOMAIN ANTIBODIES FOR CTLA4 AND DERIVED PROTEIN
MA40938A (fr) Anticorps anti-cd79b et méthodes d'utilisation desdits anticorps
DK3596116T5 (da) Variante immunmodulatoriske pd-l1-proteiner og anvendelser deraf
PE20190563A1 (es) Genes de mini-distrofina optimizados y casetes de expresion y su uso
MX382518B (es) Antigenos de citomegalovirus y su uso.
BR112019012343A2 (pt) anticorpos il-11ra
MA39248B1 (fr) Anticorps anti-jagged1 et procédés d'utilisation correspondants
MX2017008817A (es) Composiciones y metodos para la glicosilacion de proteinas.
CR20210047A (es) Proteína de unión al antígeno anti-steap1
MX2017014056A (es) Construcciones dirigidas a complejos de peptido e7 del subtipo 16 del virus de papiloma humano (hpv16-e7)/complejo principal de histocompatibilidad (mhc) y sus usos.
CU24405B1 (es) Proteínas de variantes de secuencias de aminoácidos de cry1da1 activas para lepidópteros
MX2021004533A (es) Metodos para el analisis de la composicion de la proteina de la capside viral.
MX385972B (es) Partículas y composiciones de nicotina.
CY1122644T1 (el) Πρωτεϊνες συντηξης tatk-cdkl5, συνθεσεις, φαρμακοτεχνικες μορφες και η χρηση αυτων
IL281972A (en) Methods and compositions for modulation of tau proteins
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
MX2020009465A (es) Anticuerpos anti-klk5 y metodos de uso.